Artid Amorntaveechai1, Thanaphum Osathanon2, Prasit Pavasant2, Sireerat Sooampon3. 1. Interdepartmental Program of Pharmacology, Graduate School, Chulalongkorn University, Thailand. 2. Department of Anatomy, Faculty of Dentistry, Chulalongkorn University, Thailand. 3. Department of Pharmacology, Faculty of Dentistry, Chulalongkorn University, Thailand.
Abstract
Objectives: Resveratrol and oxyresveratrol, a resveratrol derivative, possess various pharmacological activities, including anti-cancer activities. Because cancer stem cells play an important role in cancer recurrence, the aims of this study were to investigate whether resveratrol or oxyresveratrol can inhibit the expression of cancer stem cell markers under hypoxia. Materials and methods: Deferoxamine was used to mimic the hypoxic condition. The mRNA expression of cancer stem cell markers was analyzed by Real-time PCR. Flow cytometry was used to determine the number of CD-44 + and CD-105 + cells. Results: Deferoxamine dose-dependently induced the expression of cancer stem cell markers; Oct-4, Nanog, CD-44, CD-105, and CD-133. The induction of these cancer stem cells markers was inhibited when the cells were treated with either resveratrol or oxyresveratrol. Moreover, we found that resveratrol also reduced the number of CD-44 + and CD-105 + cells after deferoxamine treatment. Conclusions: Resveratrol and oxyresveratrol inhibit the expression of cancer stem cell markers and might target cancer stem cells in a hypoxia-associated tumor.
Objectives: Resveratrol and oxyresveratrol, a resveratrol derivative, possess various pharmacological activities, including anti-cancer activities. Because cancer stem cells play an important role in cancer recurrence, the aims of this study were to investigate whether resveratrol or oxyresveratrol can inhibit the expression of cancer stem cell markers under hypoxia. Materials and methods: Deferoxamine was used to mimic the hypoxic condition. The mRNA expression of cancer stem cell markers was analyzed by Real-time PCR. Flow cytometry was used to determine the number of CD-44 + and CD-105 + cells. Results: Deferoxamine dose-dependently induced the expression of cancer stem cell markers; Oct-4, Nanog, CD-44, CD-105, and CD-133. The induction of these cancer stem cells markers was inhibited when the cells were treated with either resveratrol or oxyresveratrol. Moreover, we found that resveratrol also reduced the number of CD-44 + and CD-105 + cells after deferoxamine treatment. Conclusions: Resveratrol and oxyresveratrol inhibit the expression of cancer stem cell markers and might target cancer stem cells in a hypoxia-associated tumor.
Authors: Anastasia Triantafyllou; Panagiotis Liakos; Andreas Tsakalof; Elena Georgatsou; George Simos; Sophia Bonanou Journal: Free Radic Res Date: 2006-08
Authors: Min Wang; Juan Xiao; Min Shen; Yu Yahong; Rui Tian; Feng Zhu; Jianxin Jiang; Zhiyong Du; Jun Hu; Wensong Liu; Renyi Qin Journal: Int J Cancer Date: 2011-01-01 Impact factor: 7.396
Authors: Jin Hyen Baek; Chad E N Reiter; Dominador J Manalo; Paul W Buehler; Robert C Hider; Abdu I Alayash Journal: Biochim Biophys Acta Date: 2011-05-01